• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Use of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant.

作者信息

Leung Michael, Rogers Jane E, Shureiqi Imad

机构信息

Department of Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX.

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.

出版信息

Clin Colorectal Cancer. 2021 Sep;20(3):273-278. doi: 10.1016/j.clcc.2021.03.002. Epub 2021 Apr 6.

DOI:10.1016/j.clcc.2021.03.002
PMID:33965356
Abstract
摘要

相似文献

1
Use of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant.在一名携带c.557A>G杂合DPYD变异的患者中，使用尿苷三乙酸逆转5-氟尿嘧啶暴露后的严重持续性骨髓抑制。
Clin Colorectal Cancer. 2021 Sep;20(3):273-278. doi: 10.1016/j.clcc.2021.03.002. Epub 2021 Apr 6.
2
Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.三醋酸尿苷（Vistogard）在挽救二氢嘧啶脱氢酶（DPYD）缺乏患者严重5-氟尿嘧啶毒性方面的益处。
Cancer Chemother Pharmacol. 2016 Jul;78(1):151-6. doi: 10.1007/s00280-016-3063-1. Epub 2016 Jun 8.
3
FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs.FDA 批准：三乙酸尿苷用于氟尿嘧啶或卡培他滨用药过量的患者，或这些药物给药后出现早期严重毒性的患者。
Clin Cancer Res. 2016 Sep 15;22(18):4545-9. doi: 10.1158/1078-0432.CCR-16-0638. Epub 2016 Jul 11.
4
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.基于 DPYD 基因型的氟嘧啶类药物个体化剂量在癌症患者中的应用：一项前瞻性安全性分析。
Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19.
5
Early-Onset 5-Fluorouracil Toxicity in a Patient Negative for Dihydropyrimidine Dehydrogenase Mutations: The Clinical Course of Reversal with Uridine Triacetate.二氢嘧啶脱氢酶突变阴性患者的早发性5-氟尿嘧啶毒性：尿苷三乙酸酯逆转的临床过程
Pharmacotherapy. 2016 Nov;36(11):e178-e182. doi: 10.1002/phar.1841. Epub 2016 Nov 4.
6
Case report of capecitabine toxicity and use of uridine triacetate.卡培他滨毒性及尿苷三乙酸酯应用的病例报告
J Oncol Pharm Pract. 2019 Mar;25(2):470-473. doi: 10.1177/1078155217730662. Epub 2017 Sep 25.
7
The successful treatment of 5-fluorouracil (5-FU) overdose in a patient with malignancy and HIV/AIDS with uridine triacetate.使用三乙酸尿苷成功治疗一名患有恶性肿瘤及HIV/AIDS的患者的5-氟尿嘧啶（5-FU）过量中毒。
Am J Emerg Med. 2017 May;35(5):802.e7-802.e8. doi: 10.1016/j.ajem.2016.11.038. Epub 2016 Nov 15.
8
Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA?氟嘧啶诱导的毒性与二氢嘧啶脱氢酶缺乏症：一例早期发生的致命性卡培他滨诱导毒性病例报告及文献综述。三醋酸尿苷：作为解毒剂的疗效与安全性。在美国以外地区是否可获取？
J Oncol Pharm Pract. 2020 Apr;26(3):747-753. doi: 10.1177/1078155219865597. Epub 2019 Aug 5.
9
Use of uridine triacetate for the management of fluorouracil overdose.三乙酰尿苷在氟尿嘧啶用药过量时的应用。
Am J Health Syst Pharm. 2011 Oct 1;68(19):1806-9. doi: 10.2146/ajhp100434.
10
Two patients with fluoropyrimidine overdose successfully managed without uridine triacetate.两名氟尿嘧啶类药物过量的患者在未使用尿苷三乙酸酯的情况下成功得到治疗。
J Oncol Pharm Pract. 2023 Dec;29(8):2037-2040. doi: 10.1177/10781552231189818. Epub 2023 Jul 27.

引用本文的文献

1
Economic Model of Uridine Triacetate Versus Supportive Care for the Treatment of Patients with Life-Threatening Early-Onset Severe Toxicity.尿苷三乙酸酯与支持性治疗用于治疗危及生命的早发性严重毒性患者的经济模型
Clin Drug Investig. 2025 Mar;45(3):111-123. doi: 10.1007/s40261-025-01426-x. Epub 2025 Feb 22.
2
A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice.将二氢嘧啶脱氢酶（DPYD）基因分型用于全身氟嘧啶类药物的临床实践实施指南。
Clin Pharmacol Ther. 2025 May;117(5):1194-1208. doi: 10.1002/cpt.3567. Epub 2025 Jan 31.
3
The Frequency of c.557A>G in the Dominican Population and Its Association with African Ancestry.
多米尼加人群中c.557A>G的频率及其与非洲血统的关联。
Pharmaceutics. 2024 Dec 24;17(1):8. doi: 10.3390/pharmaceutics17010008.
4
DPYD genetic polymorphisms in non-European patients with severe fluoropyrimidine-related toxicity: a systematic review.非欧洲严重氟嘧啶相关毒性患者的 DPYD 基因多态性：系统评价。
Br J Cancer. 2024 Aug;131(3):498-514. doi: 10.1038/s41416-024-02754-z. Epub 2024 Jun 17.
5
Case report: Uridine triacetate in the management of delayed onset 5-fluorouracil toxicity: A case report and review of literature.病例报告：三乙酸尿苷治疗5-氟尿嘧啶延迟性毒性：一例病例报告及文献综述
Front Pharmacol. 2022 Sep 7;13:977734. doi: 10.3389/fphar.2022.977734. eCollection 2022.